KEYTRUDA 25 mg/mL concentrate for solution for infusion, Saline solution NACl 0.9%, mRNA-4157
V940-004
Phase 2 small_molecule active
Quick answer
KEYTRUDA 25 mg/mL concentrate for solution for infusion, Saline solution NACl 0.9%, mRNA-4157 for Intermediate-high -risk RCC, high-risk RCC who have undergone nephrectomy, or M1 NED RCC who have undergone nephrectomy and metastasectomy. is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Intermediate-high -risk RCC, high-risk RCC who have undergone nephrectomy, or M1 NED RCC who have undergone nephrectomy and metastasectomy.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active